Home > Healthcare > Pharmaceuticals > Finished Drug Form > Vulvovaginal Candidiasis (VVC) Treatment Market

Vulvovaginal Candidiasis (VVC) Treatment Market Trends

Report ID: GMI9746
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Vulvovaginal Candidiasis Treatment Market Trends

Increasing prevalence of vulvovaginal candidiasis (VVC) serves as a significant driver in the market. Several factors contribute to the rising incidence of VVC, driving demand for effective treatment options and shaping the market landscape.
For instance, according to an article published in Indian Journal of Obstetrics and Gynecology Research, approximately 70-75% of women are affected by VVC at least once in their lifetime. Thus, as the prevalence of VVC continues to rise, the market is expected to expand further.
Additionally, the availability of over the counter (OTC) drugs for VVC treatment is another significant driver of market growth. This allows women to conveniently self-manage uncomplicated VVC symptoms without the need for a prescription or healthcare provider visit. This accessibility and convenience appeal to consumers, driving demand for OTC treatments and expanding the overall market.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The vulvovaginal candidiasis treatment market was valued at USD 1 billion in 2023 and is poised to grow at 4.5% CAGR during 2024-2032, attributed to the increasing prevalence of VVC worldwide.

The uncomplicated segment held 60.2% of the vulvovaginal candidiasis (VVC) treatment market share in 2023 and will grow rapidly through 2032, owing to its high prevalence.

North America vulvovaginal candidiasis treatment market was valued at USD 418.2 million in 2023 and is expected to reach USD 613.7 million by 2032, owing to the presence of a well-developed healthcare system with state-of-the-art medical facilities.

Accord Healthcare Ltd, Amneal Pharmaceuticals LLC, Astellas Pharma Inc, Basilea Pharmaceutica Ltd, Bayer AG, Bristol-Myers Squibb Company, Grupo Ferrer Internacional S.A, Johnson & Johnson, and Mycovia Pharmaceuticals, Inc. among others.